AOD-9604 vs Tesofensine

AOD-9604 and Tesofensine are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, and safety profiles to help researchers understand the key differences and overlaps.

AOD-9604, a modified peptide derived from human growth hormone (specifically the amino acids 177-191 along with an N-terminal tyrosine), was developed at Monash University, Australia. This peptide retains the lipolytic properties associated with HGH, facilitating fat metabolism while eliminating the growth-promoting and diabetogenic effects typically linked to growth hormone. Although the FDA granted AOD-9604 GRAS status for food use in 2014, its clinical development for obesity management was ultimately halted. Research suggests that AOD-9604 may promote fat loss without significantly affecting insulin levels or IGF-1, which is critical for avoiding adverse metabolic effects. Additionally, preclinical studies have indicated potential benefits in cartilage repair, although these findings require further validation through rigorous clinical trials.

Tesofensine functions as a triple monoamine reuptake inhibitor, targeting serotonin, norepinephrine, and dopamine pathways. Originally developed by NeuroSearch A/S for neurodegenerative conditions such as Alzheimer's and Parkinson's disease, it has since shifted focus towards weight management and appetite suppression. Current research indicates that Tesofensine can induce significant weight loss, with studies reporting an average reduction of approximately 10% of body weight in participants. This weight loss appears to be facilitated through appetite suppression and a reduction in caloric intake, alongside an increase in resting metabolic rate. While promising, ongoing Phase 3 trials by Saniona are necessary to confirm these effects and assess long-term safety and efficacy.

AOD-9604 and Tesofensine, while both investigated for their roles in weight management, address distinct aspects of metabolic regulation. AOD-9604 is primarily researched for its potential in fat loss, leveraging its lipolytic effects without the accompanying growth-related side effects. In contrast, Tesofensine is being studied for its broader impact on weight loss through appetite suppression and metabolic enhancement. The differing mechanisms suggest that researchers may choose one compound over the other based on the specific metabolic pathways they wish to explore, as well as the desired outcomes in their studies.

Safety profiles for AOD-9604 and Tesofensine reveal important distinctions. In extensive clinical trials, AOD-9604 demonstrated a side effect profile that was largely comparable to placebo, with mild headaches and flushing reported in a small percentage of participants. Importantly, it does not elevate IGF-1 levels, thereby mitigating concerns related to abnormal bone growth or organ enlargement. Conversely, Tesofensine, while effective, has been associated with increased heart rate and blood pressure at higher doses, as noted in Phase 2 trials. Common side effects include dry mouth, insomnia, constipation, nausea, and diarrhea. Additionally, psychiatric effects such as anxiety and mood changes have been reported, consistent with its mechanism as a monoamine reuptake inhibitor. These safety considerations are crucial for researchers when evaluating the suitability of each peptide for their studies.